Hopkinton, MA – May 8, 2025 – In a groundbreaking collaboration, Phosphorex, NOFCORPORATION, NeoSome Life Sciences, NanoImaging Services (NIS), and EnvolBiomedical have joined forces to establish the LNP Alliance, a strategicpartnership dedicated to advancing lipid nanoparticle (LNP) technology andaccelerating the development of next-generation therapeutics.
The LNP Alliance brings together deep scientific expertise, proprietary lipid innovations, world-class formulation capabilities and analytical and drug efficacy services to support biopharma and biotech companies in overcoming drug development challenges. By combining forces, theLNP Alliance provides a comprehensive, end-to-end solution encompassing lipidsynthesis, formulation development, process optimization, analytical characterization, and manufacturing support—enabling partners to efficiently move from discovery to clinical success.
“The LNP Alliance represents a unique convergence of industry leaders, each bringing specialized expertise to drive innovation in LNP-based drug development,” said Jarlath Keating, CEO of Phosphorex. “By working together, we provide a comprehensive solution that allows our partners to develop more effective therapies, faster.”
As a unified force in LNP innovation, the LNPAlliance offers:
- Access to proprietary ionizable lipids and excipients for optimized drug delivery
- Expert formulation and process development to enhance LNP stability and efficacy\Integrated analytical and manufacturing capabilities for streamlined scale-up
- Integrated analytical and manufacturing capabilities for streamlined scale-up
- Cryo-TEM imaging for nanoparticle characterization
- Bio distribution, efficacy, and toxicology evaluations in multiple animal models, including Non-Human Primates
“With our extensive experience in lipid chemistry and drug delivery technologies, NOF is proud to be part of this transformative initiative,” said Yuji Yamamoto, General Manager of NOF CORPORATION. “The LNP Alliance allows us to collaborate closely with industry partners to advance new therapeutics and bring real value to patients.”
The launch of the LNP Alliance underscores the commitment of Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NIS and Envol Biomedical to shaping the future of LNP-based drug development. Together, they are driving innovation, accelerating timelines, and empowering biopharma companies to bring groundbreaking treatments to patients in need.
For more information on the LNP Alliance and partnership opportunities, please email LNPalliance@phosphorex.com
About the LNP Alliance Partners
Phosphorex – A leading CRO / CDMO specializing in drug delivery, offering expertise in LNP formulation, process development, scale-up and analytics. Formore info, visit www.phosphorex.com
NOF CORPORATION – A global pioneer in PEG and lipid chemistry, providing high-performance ionizable lipids, PEG lipids, and excipients for advanced drug delivery applications. For more info, visit www.dds-drug.com
NeoSome Life Sciences – An innovative preclinical CRO providing comprehensive in vitro and in vivo services tosupport drug discovery and development across various therapeutic areas. For more info, visit www.neosomels.com
NanoImaging Services – A leader in cryo-electron microscopy (cryo-EM) andnanoparticle characterization, ensuring the highest quality and integrity forLNP-based therapeutics. For more info, visit www.nanoimagingservices.com
Envol Biomedical – A leading non-clinical laboratory offeringpharmacology and toxicology capabilities focused on Non-Human Primates. Formore info, visit www.envolbio.com
Media Contact
Kim Yang
Marketing Director
kyang@phosphorex.com
